Children with attention-deficit/hyperactivity disorder who receive methylphenidate may be at an increased risk of having a ...

A new study has investigated how different medications and therapies compare with placebos in treating ADHD symptoms. Attention deficit hyperactivity disorder, or ADHD, was long thought to be a ...

New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~ SAN DIEGO, CALIFORNIA / ACCESS ...

A new study suggests that common medications prescribed to help manage ADHD, such as Adderall and Ritalin, may work ...

Launches of Tuzulby® methylphenidate prolonged-release chewable tablets and Paxneury® guanfacine prolonged-release tablets, also in 5mg, 6mg, and 7mg strengthsTwo differentiated treatments exemplify ...

Attention deficit hyperactivity disorder (ADHD) is a condition characterized by inattention, hyperactivity and impulsivity.

This graph visualizes how the trials included in the meta-analysis compared the effectiveness of different treatment strategies. The width of the lines connecting each treatment reflects the number of ...

German CNS-focused specialist Neuraxpharm Group announced the launches in Europe of Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) ...

ADHD is a disorder with symptoms of inattention such as distractibility and disorganization. It can also include hyperactivity and impulsivity in some but not all individuals. ADHD begins in childhood ...

For many women, the transition to parenthood is a life-altering event filled with new challenges and responsibilities. A new ...

Are you or your loved one struggling with the overwhelming effects of trauma, PTSD, or substance abuse? Perhaps your child is facing challenges with ADHD, autism spectrum disorders, or behavioral ...

Henry Shelford, chief executive of charity ADHD UK, warned that the dropping of shared care was dangerous for patients facing ...